Innate Pharma said it will concentrate on the development of monoclonal antibodies while halting the development of some experimental drugs, including IPH 1101 for the indication of chronic blood cancer and two RNA-based drug candidates. "The [RNA candidate] projects will not be binned, but we will try to find buyers to continue them," said Laure-Helene Mercier, head of the firm's investor relations.

Full Story:

Related Summaries